Endocrinology

Back to articles

New position statement promotes hormone therapy for select postmenopausal women

KEY POINT

A new position statement released by the North American Menopause Society on hormone replacement therapy (HRT) noted that the benefits of HRT may outweigh the risks for management of vasomotor symptoms and genitourinary symptoms, prevention of bone loss, and reduction in fracture risk in women who are younger than 60 years of age, within 10 years of menopause onset, and do not have known contraindications to use. However, HRT may be associated with rare but increased risks of cardiovascular and thromboembolic events and breast cancer in women aged 60 years or older and for those who are more than 10 years from menopause onset.

SOURCES

The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.